These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 18564009)

  • 21. Should one vaccinate patients with chronic liver disease for hepatitis A virus in India?
    Anand AC; Nagpal AK; Seth AK; Dhot PS
    J Assoc Physicians India; 2004 Oct; 52():785-7. PubMed ID: 15909855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prevalence of anti-HAV antibodies in Warsaw population].
    Janaszek-Seydlitz W; Bucholc B; Wiatrzyk A
    Przegl Epidemiol; 2007; 61(4):675-82. PubMed ID: 18572499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence.
    Van Herck K; Van Damme P
    J Med Virol; 2001 Jan; 63(1):1-7. PubMed ID: 11130881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-benefit analysis of hepatitis a vaccination in Thailand.
    Teppakdee A; Tangwitoon A; Khemasuwan D; Tangdhanakanond K; Suramaethakul N; Sriratanaban J; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):118-27. PubMed ID: 12118439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule.
    Keystone JS; Hershey JH
    Int J Infect Dis; 2008 Jan; 12(1):3-11. PubMed ID: 17643334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of vaccination against hepatitis A in HIV infected adults from Lodz region--preliminary report].
    Jabłonowska E; Kuydowicz J; Małolepsza E
    Przegl Epidemiol; 2008; 62(3):605-12. PubMed ID: 19108525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of hepatitis A virus antibodies among a sample of Egyptian children.
    Al-Aziz AM; Awad MA
    East Mediterr Health J; 2008; 14(5):1028-35. PubMed ID: 19161074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis A and travel amongst Nova Scotia postsecondary students: evidence for a targeted vs. universal immunization strategy.
    Matheson K; Halperin B; McNeil S; Langley JM; Mackinnon-Cameron D; Halperin SA
    Vaccine; 2010 Nov; 28(51):8105-11. PubMed ID: 20955828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined vaccine against hepatitis A and B].
    Pawłowska M; Halota W; Kozielewicz D
    Przegl Epidemiol; 2004; 58 Suppl 1():66-70. PubMed ID: 15807160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use.
    André F; Van Damme P; Safary A; Banatvala J
    Expert Rev Vaccines; 2002 Jun; 1(1):9-23. PubMed ID: 12908508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C.
    Myers RP; Gregor JC; Marotta PJ
    Hepatology; 2000 Apr; 31(4):834-9. PubMed ID: 10733536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with hepatitis A and B vaccines.
    Davis JP
    Am J Med; 2005 Oct; 118 Suppl 10A():7S-15S. PubMed ID: 16271535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization.
    Domínguez A; Bruguera M; Plans P; Costa J; Salleras L
    J Med Virol; 2004 Jun; 73(2):172-6. PubMed ID: 15122789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults.
    Rosenthal P
    Hepatology; 2003 Jan; 37(1):44-51. PubMed ID: 12500187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to hepatitis A vaccine in HIV-positive patients.
    Weissman S; Feucht C; Moore BA
    J Viral Hepat; 2006 Feb; 13(2):81-6. PubMed ID: 16436125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults.
    Hammitt LL; Bulkow L; Hennessy TW; Zanis C; Snowball M; Williams JL; Bell BP; McMahon BJ
    J Infect Dis; 2008 Dec; 198(12):1776-82. PubMed ID: 18976095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of liver diseases in Korea: hepatitis A.
    Kwon SY
    Korean J Hepatol; 2009 Dec; 15 Suppl 6():S7-12. PubMed ID: 20037282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.